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Accurate measurement of glomerular filtration rate (GFR) is
complicated and costly; therefore, GFR is commonly
estimated by assessing creatinine or cystatin C
concentrations. Because estimates based on cystatin C
predict cardiovascular disease better than creatinine, these
estimates have been hypothesized to be superior to those
based on creatinine, when the GFR is near the normal range.
To test this, we measured GFR by iohexol clearance in a
representative sample of middle-aged (50–62 years)
individuals in the general population, excluding those with
coronary heart or kidney disease, stroke or diabetes mellitus.
Bias, precision (median and interquartile range of estimated
minus measured GFR (mGFR)), and accuracy (percentage of
estimates within 30% of mGFR) of published cystatin C and
creatinine-based GFR equations were compared in a total of
1621 patients. The cystatin C-based equation with the
highest accuracy (94%) had a bias of 3.5 and precision of
18ml/min per 1.73m2, whereas the most accurate (95%)
creatinine-based equation had a bias of 2.9 and precision of
15ml/min per 1.73m2. The best equation, based on both
cystatin C and creatinine, had a bias of 7.6ml/min per
1.73m2, precision of 15ml/min per 1.73m2, and accuracy of
92%. Thus, estimates of GFR based on cystatin C were not
superior to those based on creatinine in the general
population. Hence, the better prediction of cardiovascular
disease by cystatin C than creatinine measurements, found
by others, may be due to factors other than GFR.
Kidney International (2010) 78, 1305–1311; doi:10.1038/ki.2010.321;
published online 15 September 2010
KEYWORDS: cardiovascular disease; clinical nephrology; Cockcroft–Gault;
creatinine; glomerular filtration rate
Chronic kidney disease has been established as a risk factor
for cardiovascular disease.1 Reduction in the glomerular
filtration rate (GFR) near the normal range is also being
studied as a potential risk factor of cardiovascular disease in
the general population. Because measuring GFR accurately in
surveys is complicated and costly, GFR has been estimated
from creatinine or cystatin C. In community-based and
patient studies, cystatin C-based estimates have been superior
to creatinine in predicting cardiovascular disease.2–4 The
putative explanation is that cystatin C may be more sensitive
to small reductions in GFR and better for estimating GFR
near the normal range than creatinine.5
Creatinine-based GFR estimates have been found to be
biased and imprecise for GFR values in the normal range.6–11
One reason for this bias is that, in contrast to cystatin C, the
production rate of creatinine depends on muscle mass, which
varies significantly in both health and disease. Also, the
creatinine-based equations that are currently used were
developed from creatinine measurements using Jaffe’s
method, which is unspecific and has been replaced by
improved enzymatic methods in many laboratories.12
However, cystatin C may be a less ideal filtration marker
than initially thought. Some studies have reported that
cystatin C is influenced by confounders not related to GFR,
such as age, gender, C-reactive protein, and albumin.13,14
Thus, a superior ability to predict cardiovascular disease does
not necessarily imply that cystatin C produces better
GFR estimates. In fact, cystatin C- and creatinine-based
GFR estimates have never been compared with precise GFR
measurements in the general population. Similarly, the
question of whether cystatin C offers better assessments of
GFR than creatinine in this setting is not yet answered.15
In the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-
T6), we studied a representative sample of middle-aged persons
from the general population using measurements of GFR
obtained by iohexol clearance, plasma creatinine measured using
an enzymatic method, and cystatin C. Our aim was to compare
published cystatin C-based equations with the most commonly
used creatinine-based equations and to validate both against
iohexol clearance.
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RESULTS
Of the 3564 individuals aged 50–62 years who completed the
main part of the sixth Tromsø population survey (Tromsø 6),
739 reported a previous myocardial infarction, angina
pectoris, stroke, diabetes mellitus, or renal disease. The
remaining 2825 eligible subjects were invited to participate in
RENIS-T6. Of the 2107 individuals who responded positively,
12 were excluded owing to an allergy to contrast media,
iodine, or latex; 65 owing to other reasons; and 48 did not
appear at their appointments. A total of 1982 subjects
remained for potential inclusion, of which 1632 were
investigated according to a predefined target.
Five participants were excluded because their iohexol
clearance measurements were technical failures. Accordingly,
the RENIS-T6 cohort consists of 1627 subjects. None of the
subjects had measured GFR (mGFR) lower than 15ml/min
per 1.73m2 (0%, 95% confidence interval 0–0.21%). Two
persons (0.12%, 95% confidence interval 0.02–0.43%) had
mGFR in the interval 15–29ml/min per 1.73m2, and 32
persons (2.0%, 95% confidence interval 1.4–2.7%) in the
interval 30–59ml/min per 1.73m2. For the present analysis,
six subjects were excluded because they used prednisolone.
The characteristics of the 1621 subjects included in the study
are compared with the total group of eligible subjects
(n¼ 2825) in Table 1. There were statistically significant,
though small, differences in age and body mass index
(Po0.01). Mean (s.d.) mGFR for women was 87.8 (14) and
for men 95.7 (13.7) ml/min per 1.73m2.
The bias, precision, and accuracy of the investigated
equations in Table 2 are shown in Table 3. For GFR estimates
based on cystatin C (estimated GFR (eGFRcys)), percentage
bias varied between 1 and 37, and percentage precision
between 21 and 37. Calibrated cystatin C improved bias and
precision for Grubb’s equation, which is based on the Dako
particle-enhanced turbidimetric immunoassay (Dakocyto-
mation, Glostrup, Denmark), but had the opposite effect on
those based on the Dade-Behring particle-enhanced nephelo-
metric immunoassay (Siemens, Marburg, Germany). Of the
eGFRcys equations, Rule’s and Stevens’ A equations with
uncalibrated cystatin C had percentage precision and P30
comparable to GFR estimated from creatinine (eGFRcre).
Both the Modification of Diet in Renal Disease (MDRD) and
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equations were nearly unbiased with percentage biases
of 1 and 3, respectively. The Cockcroft–Gault (CG) and CKD-
EPI equations were significantly more precise than all
eGFRcys equations. Accuracy, expressed as P30, was highest
for the CKD-EPI equation (95%). The two equations based
on both cystatin C and creatinine (eGFRcomb) performed at a
level between eGFRcys and eGFRcre (Table 3). Calibration
markedly worsened the performance of Stevens’ B equation.
Figure 1 shows the relationships between mGFR and eGFR
for the eGFRcre, eGFRcys, and eGFRcomb equations with the
highest P30. Local regression of mGFR on eGFR (dashed gray
lines) demonstrates that Stevens’ A eGFRcys equation tended
to overestimate mGFR for higher eGFRs (Figure 1a). The
same was true for Stevens’ B eGFRcomb equation (Figure 1c).
The CKD-EPI eGFRcre equation was essentially unbiased
across the range of eGFR (Figure 1b). Because the CKD-EPI
equation has different parameters for low and high creati-
nine values, the shape of the distribution of observation
in Figure 1b differed from the cigar-shaped distributions in
Figure 1a and c.
The correlation coefficients between eGFRcys and mGFR
were between 0.50 and 0.58. The coefficients for the MDRD
and CKD-EPI equations were 0.56 and 0.55, respectively. The
correlation coefficient for Stevens’ combined equations
reached 0.65, which was significantly higher than all of the
other equations. All the analyses in Table 2 were repeated for
each gender separately (not shown). We found no evidence of
superior performance of any of the cystatin C-based
equations for either men or women.
Except for the CG and Rule’s equation with uncalibrated
cystatin C, all of the equations had o0.50 sensitivity and
40.85 specificity for discrimination at GFR 60 and 80ml/
min per 1.73m2 (Table 4). The corresponding areas under
the receiver operating characteristic curves were similar for
both eGFRcys and eGFRcre (0.73–0.81; Table 4), but were
slightly higher for the combined equations.
DISCUSSION
To the best of our knowledge, this is the first study in which
equation-based GFR estimates are compared with mGFR in a
population survey. A recent study demonstrated that single-
sample iohexol clearance is as reliable as the multi-sample
method when validated against Cr-EDTA clearance.16 We
found no evidence that equations based on cystatin C alone
or in combination with creatinine provide better GFR
estimates in middle-aged members of the general population
than the commonly used MDRD and CKD-EPI equations.
Two reviews on GFR estimates among persons with reduced
GFR have pointed out that some studies show a better
performance of cystatin C than creatinine, whereas others
have found the two markers to be equivalent.17,18 Louvar
et al.19 found the MDRD equation to be better than eGFRcys
in a follow-up of former kidney donors.
Table 1 | Study population characteristics compared with all
eligible subjects
Included
(n=1621)
All eligible
persons
(n=2825)a
Female (%) 50.7 50.7
Mean age (s.d.), years 56.9b (3.9) 56.8 (3.9)
Mean weight (s.d.), kg 78.7 (14.4) 78.3 (14.5)
Mean height (s.d.), cm 170.6 (8.7) 170.7 (9.0)
Mean body mass index (s.d.), kg/m2 26.9b (4.0) 26.8 (4.0)
Mean plasma creatinine (s.d.), mmol/l 68.5 (12.8) 68.8 (12.5)
Mean plasma cystatin C (s.d.), mg/l 0.78 (0.12) 0.78 (0.11)
Meanmeasured GFR (s.d.), ml/min per 1.73m2 91.7 (14.4)
aMeans and s.d. weighted according to the age stratification and gender
stratification of RENIS-T6.
bPo0.01 for difference between included and eligible.
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The performance of the MDRD and CKD-EPI equations
was good. Bias and accuracy were better for the MDRD
equation than that reported in two other external valida-
tions.7,20 The bias was substantially smaller than in several
investigations of potential kidney donors9–11 and chronic
kidney disease patients with near normal GFR,6,8 but similar
to the investigation of former kidney donors by Sebasky
et al.21 and potential kidney donors by Froissart et al.22 The
two eGFRcomb equations had bias and accuracy values
midway between those of the equations based on either
marker alone, and a precision similar to eGFRcre (Table 3).
Several factors may have contributed to the large bias of
most of the eGFRcys equations. The most important factor
was probably that they were all developed in populations
with chronic kidney disease and low GFR. The influence of
non-GFR factors on plasma cystatin C may differ between
Table 2 | Investigated cystatin C-based equations
Equation Authorref. Assay Manufacturer
(80.35/cystatin C)4.32 Hoek, 200337 PENIA Dade-Behring/Siemens
(100/cystatin C)14 Tidman, 200838 A PETIA Gentian
79.901  cystatin C1.4389 Flodin, 200739 PETIA Gentian
77.24  cystatin C1.2623 Larsson, 200440 PENIA Dade-Behring/Siemens
66.8  cystatin C1.30 Rule, 200641 PENIA Dade-Behring/Siemens
86.49  cystatin C1.686  (0.948 if female) Grubb, 200542 PETIA Dako
127.7  cystatin C1.17  age0.13  (0.91 if female; 1.06 if black) Stevens, 200843 A PENIA Dade-Behring/Siemens
177.6  creatinine0.65  cystatin C0.57  age0.20  (0.82 if female; 1.11 if black) Stevens, 200843 B PENIA Dade-Behring/Siemens
Mean of MDRD equation and (100/cystatin C)14 Tidman, 200838 B PETIA Gentian
Abbreviations: MDRD, modification of diet in renal disease; PENIA, particle-enhanced nephelometric immunoassay; PETIA, particle-enhanced turbidimetric immunoassay.
Table 3 | Comparison of GFR-estimating equations based on cystatin C, creatinine, and both
Difference from mGFRa,
ml/min per 1.73m2
Percent difference
from mGFRb
Median
(95% CI)
Interquartile
range (95% CI)
Median
(95% CI)
Interquartile
range (95% CI)
P30
c, %
(95% CI)
Correlation
with mGFR,
coefficient
(95% CI)
Cystatin C-based equations (uncalibrated cystatin C)
Flodin, 200739 21.0 (19.8 to 22.3) 26.3 (24.8–27.8) 23 (22 to 25) 30 (28–31) 62 (60–64) 0.50 (0.47–0.54)
Grubb, 200542 34.4 (32.8 to 36.1) 32.7 (30.9–34.6) 37 (35 to 39) 37 (35–39) 39 (36–41) 0.53 (0.50–0.57)
Hoek, 200337 5.9 (4.9 to 6.9) 18.6 (17.4–19.8) 7 (6 to 8) 21 (19–22) 91 (89–92) 0.51 (0.47–0.55)
Larsson, 200440 12.8 (11.7 to 13.7) 21.9 (20.6–23.1) 14 (13 to 15) 25 (24–27) 78 (76–80) 0.51 (0.47–0.54)
Tidman, 200838 A 21.1 (20.0 to 21.9) 21.4 (20.2–22.6) 23 (22 to 24) 25 (24–27) 63 (60–65) 0.51 (0.47–0.55)
Rule, 200641 0.7 (1.4 to 0.2) 20.2 (19.1–21.4) 1 (1 to 0) 23 (21–24) 93 (91–94) 0.51 (0.47–0.54)
Stevens, 200843 A 3.5 (2.7 to 4.6) 18.4 (17.3–19.6) 4 (3 to 5) 21 (20–22) 94 (92–95) 0.58 (0.55–0.61)
Cystatin C-based equations (calibrated cystatin C)
Grubb, 200542 16.5 (15.4 to 17.7) 23.3 (22.1–24.6) 18 (17 to 20) 27 (25–28) 72 (69–74) 0.55 (0.51–0.58)
Hoek, 200337 20.7 (19.5 to 21.7) 22.4 (21.1–23.8) 22 (21 to 24) 27 (25–28) 64 (62–67) 0.51 (0.47–0.54)
Larsson, 200440 31.8 (30.5 to 32.9) 29.4 (27.6–31.2) 35 (33 to 37) 33 (31–35) 42 (40–45) 0.50 (0.46–0.54)
Rule, 200641 16.7 (15.6 to 18.1) 26.6 (25.1–28.3) 19 (17 to 20) 30 (28–32) 68 (66–71) 0.50 (0.46–0.54)
Stevens, 200843 A 19.2 (18.2 to 20.4) 23.9 (22.7–25.3) 21 (20 to 23) 27 (26–29) 66 (64–69) 0.57 (0.53–0.60)
Cystatin C- and creatinine-based equations (uncalibrated cystatin C)
Stevens, 200843 B 7.6 (7.1 to 8.4) 14.9 (14.1–15.9) 8 (8 to 9) 17 (16–18) 92 (90–93) 0.65 (0.62–0.68)
Tidman, 200838 B 11.8 (11.2 to 12.5) 15.7 (14.8–16.6) 13 (12 to 14) 18 (17–19) 87 (85–89) 0.62 (0.59–0.66)
Cystatin C- and creatinine-based equation (calibrated cystatin C)
Stevens, 200843 B 15.6 (14.5 to 16.4) 16.8 (15.9–17.9) 17 (16 to 18) 19 (18–20) 81 (79–82) 0.65 (0.62–0.68)
Creatinine-based equations
Cockcroft–Gault 14.5 (15.4 to 13.9) 16.3 (15.2–17.3) 16 (17 to 15) 16 (15–17) 91 (90–92) 0.48 (0.45–0.52)
MDRD 1.3 (0.4 to 2.1) 18.2 (17.0–19.5) 1 (0.4 to 2.3) 20 (19–22) 93 (91–94) 0.56 (0.52–0.60)
CKD-EPI 2.9 (2.2 to 3.5) 15.4 (14.5–16.3) 3 (2.3 to 3.9) 17 (16–19) 95 (94–96) 0.55 (0.52–0.59)
Abbreviations: CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in
renal disease; mGFR, measured GFR.
aeGFRmGFR
b100 (eGFRmGFR)/mGFR.
cP30 is defined as the proportion of eGFR within 30% of mGFR.
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these patients and the general population.13,14 Also, standar-
dization between assays and laboratories, where substantial
progress has been made for creatinine, is lacking for cystatin
C.23 We used published results to calibrate our measurements
of cystatin C to the other methods, but this resulted in a
better performance of the Dako-based Grubb equation and
worse results for equations developed with Dade-Behring’s
assay. The lack of standardization is a serious obstacle for the
routine use of eGFRcys.
The sensitivity of any of the equations for detecting an
mGFR ofo60ml/min per 1.73m2 wasp30% (Table 4). The
confidence intervals of the sensitivities were wide because
there were few persons in this group, but their upper limits
were also well below 50%. Specificities at 100% indicate poor
calibration, but areas under the receiver operating character-
istic curve of 0.72–0.80 demonstrate that none of the
equations discriminated well at this cutoff point. The results
for detecting a GFR of o80ml/min per 1.73m2 were also
poor. However, as most of the low mGFRs to be detected
were clustered in the range immediately below each cutoff,
any equation would have difficulty in obtaining a high
sensitivity because anything short of nearly perfect precision
would give many false negatives by chance. Better results have
been found in populations with a higher proportion of very
low GFR values.20 This is an example of the so-called
‘spectrum bias’.24 Our results indicate that screening for low
GFR with creatinine or cystatin C in a low-risk general
population is probably not worthwhile.
Although they did not perform better than eGFRcre, the
combined equations had a significantly higher correlation
with mGFR than both eGFRcre and eGFRcys, which would, in
principle, make, for example, Stevens’ B equation a better
proxy variable for mGFR when predicting cardiovascular
disease. However, a recent population-based study found that
there was a weaker association between overall and
cardiovascular mortality and Stevens’ B (eGFRcomb) than
Stevens’ A (eGFRcys).
3 Overestimation of GFR in persons
with chronic disease and low muscle mass owing to the
creatinine term in the equation was thought to be the reason.
Our results suggest that the dependence of cystatin C on non-
GFR factors should be considered as an alternative explana-
tion.13,14
One limitation of the present study was that it was
restricted to persons between 50 and 62 years of age.
However, studies with a wider age range have not reported
interactions between age and cystatin C or creatinine that
would lead us to expect better results for eGFRcys in other age
groups. Because our study population included Caucasians
only, we were not able to study the effect of ethnicity.
This study did not include persons with self-reported
cardiovascular disease or diabetes mellitus. It is possible that
cystatin C may perform better than creatinine in these
individuals, but there is also the risk that the performance
may be confounded by factors influencing both cardio-
vascular risk and the production rate of cystatin C or
creatinine.13,14 Estimating the performance of cystatin C- and
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Figure 1 |Comparison of measured and estimated GFR. Comparison of measured and estimated GFR (eGFR) for Stevens’ A (a), CKD-EPI
(b), and Stevens’ B equations (c) on the log scale. The straight line represents identity, and the gray area indicates where the eGFR is
within 30% of the measured GFR. Local regression of measured on estimated GFR by the loess method in SAS is indicated by the gray
dashed lines. Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate.
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creatinine-based equations without this source of confound-
ing was one of the strengths of the present study.
We conclude that published equations for estimating
GFR from cystatin C alone or combined with creatinine
do not estimate GFR better in the general population than
the creatinine-based MDRD and CKD-EPI equations. This
finding suggests that the superior prediction of cardiovas-
cular disease by cystatin C-based GFR estimates reported by
others may be the result of non-GFR determinants of plasma
cystatin C concentration.
METHODS
Subjects
The Tromsø Study is a population-based prospective survey in the
municipality of Tromsø, North Norway (current population
65,000). Since 1974, the Tromsø Study has carried out six health
surveys that invited total birth cohorts and random population
samples to participate. The main emphasis of the study is on
cardiovascular and other chronic diseases. RENIS-T6 is an ancillary
part of Tromsø 6. In the main part of the Tromsø 6 survey, a
representative sample of 12,984 adults participated between October
2007 and December 2008. The participation rate was 66%. Those
invited to Tromsø 6 included a 40% random sample of individuals
aged 50–59 years and all individuals aged 60–62 years (5464 total
subjects). Of these subjects, 3564 individuals between 50 and 62
years of age completed the main part of Tromsø 6 (65%).
From this group of 3564 subjects, those who did not report a
previous myocardial infarction, angina pectoris, stroke, diabetes
mellitus, or any renal disease (except urinary tract infection) were
invited to participate in RENIS-T6 and were included in the study,
stratified according to gender and age in a consecutive order until a
predetermined target of 1600 subjects was met. Individuals using
anti-diabetic medication, pregnant women, and individuals report-
ing allergies to contrast media, iodine, or latex were excluded. In the
present analysis, individuals taking medication that influences
creatinine or cystatin C pharmacokinetics independently of GFR
(cimetidine, trimethoprim, pyrimethamine, calcitriol, alphacalcidol,
and steroids) were also excluded.18,25
This study was approved by the Norwegian Data Inspectorate
and the Regional Ethics Committee of North Norway. All subjects
provided written consent.
Measurements
Iohexol clearance. mGFR was measured using single-sample
plasma clearance of iohexol at the Clinical Research Unit at the
University Hospital of North Norway. This method has been
validated against gold standard methods for measuring GFR.16,26–31
The subjects were instructed to avoid large meals with meat and
non-steroid anti-inflammatory drugs 2 days before the investigation,
which was performed after fasting, including abstinence from
nicotine. The investigation was re-scheduled if the patient suffered
from any acute illness or had a radiological examination using
contrast within a week before. The subjects were reminded to not
restrict the intake of water. A Teflon catheter was placed in an
antecubital vein, and a null sample and blood samples for creatinine
and cystatin C were drawn. A total of 5ml of iohexol (Omnipaque,
300mgI/ml; Amersham Health, London, UK) was injected, and the
syringe was weighed before and after the injection. The catheter was
flushed with 30ml isotonic saline and used for iohexol analysis
Table 4 | Diagnosis of low GFR by cystatin C- and creatinine-based equations for estimating GFR
GFR o60ml/min per 1.73m2 GFRo80ml/min per 1.73m2
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Area under
ROC-curve (95% CI)
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Area under
ROC-curve (95% CI)
Cystatin C-based equations (uncalibrated cystatin C)
Flodin, 200739 21 (8–35) 100 (100–100) 0.769 (0.679–0.850) 20 (15–25) 98 (97–99) 0.768 (0.738–0.796)
Grubb, 200542 21 (8–35) 100 (100–100) 0.785 (0.698–0.864) 15 (11–19) 99 (98–99) 0.784 (0.756–0.811)
Hoek, 200337 21 (8–35) 100 (100–100) 0.770 (0.679–0.850) 26 (21–31) 96 (95–97) 0.768 (0.738–0.796)
Larsson, 200440 21 (8–35) 100 (100–100) 0.770 (0.679–0.851) 22 (18–27) 97 (96–98) 0.768 (0.738–0.796)
Tidman, 200838 A 9 (3–20) 100 (100–100) 0.770 (0.679–0.850) 10 (7–14) 99 (99–100) 0.768 (0.738–0.796)
Rule, 200641 30 (15–46) 99 (98–99) 0.770 (0.679–0.851) 51 (45–57) 83 (81–85) 0.768 (0.738–0.796)
Stevens, 200843 A 27 (13–42) 99 (99–100) 0.809 (0.727–0.883) 43 (38–49) 91 (89–92) 0.806 (0.779–0.832)
Cystatin C-based equations (calibrated cystatin C)
Grubb, 200542 21 (8–35) 100 (99–100) 0.785 (0.698–0.864) 24 (19–29) 98 (97–98) 0.784 (0.756–0.811)
Hoek, 200337 9 (3–20) 100 (100–100) 0.770 (0.679–0.850) 11 (8–15) 99 (99–100) 0.768 (0.738–0.796)
Larsson, 200440 15 (4–28) 100 (100–100) 0.770 (0.679–0.851) 10 (7–14) 99 (99–100) 0.768 (0.738–0.796)
Rule, 200641 24 (10–39) 100 (99–100) 0.770 (0.679–0.851) 25 (20–30) 97 (96–98) 0.768 (0.738–0.796)
Stevens, 200843 A 21 (8–35) 100 (100–100) 0.804 (0.721–0.880) 20 (16–25) 98 (98–99) 0.802 (0.775–0.829)
Cystatin C- and creatinine-based equations (uncalibrated cystatin C)
Stevens, 200843 B 15 (4–28) 100 (100–100) 0.802 (0.709–0.881) 30 (25–35) 97 (96–98) 0.835 (0.810–0.858)
Tidman, 200838 B 12 (3–24) 100 (100–100) 0.789 (0.697–0.869) 17 (13–21) 99 (99–100) 0.822 (0.796–0.847)
Cystatin C- and creatinine-based equation (calibrated cystatin C)
Stevens, 200843 B 15 (4–28) 100 (100–100) 0.802 (0.709–0.881) 16 (12–20) 99 (98–99) 0.835 (0.810–0.858)
Creatinine-based equations
Cockcroft–Gault 24 (10–39) 97 (96–98) 0.728 (0.628–0.816) 87 (83–90) 44 (42–47) 0.741 (0.711–0.770)
MDRD 18 (6–32) 100 (99–100) 0.763 (0.666–0.851) 49 (43–55) 87 (86–89) 0.783 (0.755–0.810)
CKD-EPI 18 (6–32) 100 (100–100) 0.764 (0.667–0.848) 27 (22–32) 96 (95–97) 0.785 (0.760–0.811)
Abbreviations: CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease;
ROC, receiver operating characteristic.
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samples.30 The subjects were observed for allergic reactions for
30min and then allowed to walk about freely and eat a light
breakfast, but they were not allowed to eat meat or to smoke. The
optimal time for measuring iohexol concentration after injection
was calculated by Jacobsson’s method based on the GFR estimated
from creatinine.32 To ensure complete distribution of iohexol in the
extracellular fluid volume, the shortest sampling time was set at
180min. The exact time from injection to sampling was measured in
minutes using a separate stopwatch for each person.
Omnipaque from one batch purchased from Amersham was
used. The serum iohexol concentration was measured by high
performance liquid chromatography as previously described by
Nilsson-Ehle.33 Proteins were precipitated by adding 800 ml
0.33mol/l perchloric acid to 200 ml serum. After centrifugation,
10 ml supernatant was injected on a 4 200mm Nucleosil 5 mm 100
C18 column (Hichrom, Theale, Reading, UK). The mobile phase
contained 95% (v/v) citric acid/citrate buffer, 20mol/l, pH 4.5 and
5% acetonitrile and was maintained at a flow of 0.9ml/min. After
elution of both iohexol isomers (10min), the column was washed
with 100% methanol during 1.5min at a flow of 0.9ml/min. The
concentration of iohexol was calculated from the area under the
largest iohexol peak as compared with suitable external standards of
iohexol. The coefficient of variation for the analysis during the study
period was 3%. The external quality control was provided by Equalis
(Equalis AB, Uppsala, Sweden).
The GFR was calculated using the formulae described by
Jacobsson.32 The following system of three equations for correction
for non-immediate mixing (r), correction for non-uniform distribu-
tion (m), and iohexol clearance in ml/min (Cl) was solved with a
numeric method from the extracellular volume in ml (V), time in
minutes from injection to sampling (t), concentration of iohexol in
mg/l (C(t)) at time t, and amount of injected iohexol in mg (Q(0)):
r ¼0:495 1þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 0:0049Cl
p 
m ¼0:991 0:00122Cl
Cl ¼ 1ðtm=VÞ  lnðrÞ=Cl ln
Qð0Þ
CðtÞV=m
 
Extracellular volume (V) was estimated by Granerus’ equation.34
Extra-renal iohexol clearance was ignored in accordance with the
practice of other authors. GFR was normalized to 1.73m2 body surface
area, which was estimated using Dubois’ equation.35
Creatinine. Plasma creatinine analyses were performed on the
Hitachi Modular model using an enzymatic method that has been
standardized against isotope dilution mass spectroscopy (CREA Plus,
Roche Diagnostics, GmbH, Mannheim, Germany). The laboratory
participated in an external quality assessment program provided by
Labquality, Helsinki, Finland. The analysis at our laboratory was
calibrated with serum X in the Nordic Reference Interval Project,
which has been validated against isotope dilution mass spectroscopy.36
Inter-assay coefficient of variation in the study period was 2.3%.
Cystatin C. Cystatin was measured by particle-enhanced
turbidimetric immunoassay using reagents from Gentian (Gentian,
Moss, Norway) on a Modular E analyzer (Roche Diagnostics). Inter-
assay coefficient of variation in the study period was 3.1%.
Estimating equations
Equations for eGFRcys and eGFRcomb are presented in Table 2.
37–43
Equations for adults with a kidney transplant or those developed for
specific diagnostic groups were excluded.
There are three different commercially available cystatin C assays:
Dako (Dakocytomation), Dade-Behring (Siemens), and Gentian
(Gentian). The Gentian and Dako assays are particle-enhanced
turbidimetric immunoassays, whereas the Dade-Behring assay is a
particle-enhanced nephelometric immunoassay. Each of the esti-
mating equations was developed for one of these assays, which are
known to give somewhat different results. Delanaye et al.23
compared the three methods and established the linear relationships
between them. We studied both uncalibrated cystatin C measure-
ments and measurements calibrated to Dade-Behring or Dako, as
appropriate, according to the regression equations from Delanaye’s
work (Table 5 of Delanaye et al.23): cystatin CDako¼ (cystatin
CGentian 0.8908)þ 0.1593; and cystatin CDade-Behring¼ (cystatin
CGentian 1.0247)0.1173.
The creatinine-based equations investigated in the present
study were the recalibrated four-variable MDRD, CKD-EPI, and
CG equations. The MDRD equation is 175 (creatinine/
88.4)1.154 age0.203 1.212 (if black) 0.742 (if female).44 The
CKD-EPI equation is 141min(creatinine/k, 1)amax(creatinine/
k, 1)1.209 0.993age 1.018 (if female) 1.159 (if black), where
k is 62 for females and 80 for males, a is 0.329 for females
and 0.411 for males, min indicates the minimum of creatinine/k
or 1, and max indicates the maximum of creatinine/k or 1.45 The
CG equation normalized to 1.73m2 body surface area is
((140age) body weight 1.73/(creatinine 0.8 body surface
area)) 0.85 (if female).46 Creatinine was expressed in mmol/l,
body weight in kg, and body surface area in m2. When used in the
CG equation, creatinine measurements were calibrated back to the
Jaffe’s method based on the comparison between the two methods
performed when the Jaffe’s method was replaced at our hospital.
All the estimating equations give eGFR as ml/min per 1.73m2.
Statistical methods
Comparison of differences between included and eligible persons in
Table 1 were done with analysis of covariance adjusted for age and
gender. The means and s.d. of characteristics of all eligible persons
were weighted according to the age stratification and gender
stratification of RENIS-T6.
Bias and precision were calculated as the median and interquartile
range of eGFR–mGFR, respectively; percentage bias and precision as
the median and interquartile range of 100 (eGFRmGFR)/mGFR,
respectively; and accuracy as the percentage of subjects in which
absolute percentage bias was o30% (P30). Pearson’s correlation
coefficient with mGFR was estimated for each equation. The
sensitivity and specificity for detecting a GFR o60 and o80ml/min
per 1.73m2 were calculated for each equation. The area under the
receiver operating characteristic curve for each of the cutoffs was
calculated by estimating the c-statistic for a logistic model with the
GFR estimate in question as the only independent variable.
The bootstrap method was used to determine 95% confidence
intervals from 2000 re-samples of the original observations.47
To explore variation in bias across the range of eGFR, mGFR was
regressed on eGFR with local regression and displayed in a scatterplot of
mGFR vs eGFR for the three equations with the highest P30 among the
equations based on cystatin C, creatinine, and both, respectively. PROC
SGPLOT in SAS (SAS Institute, Cary, NC, USA) was used.
All analyses were performed using SAS version 9.2 (SAS
Institute). Significance was set at Po0.01.
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